|
Myeloid Leukemia, Chronic
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative chronic myelogenous leukemia (CML), 2 (18%) of 11 patients with megakaryocytic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with myelodysplastic syndromes.
|
16037387 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
JAK2 mutation was not detected in Ph+ chronic myeloid leukemia (n = 5), acute myeloid leukemia (n = 10), acute lymphoblastic leukemia (n = 10), secondary erythrocytosis (n = 10), or normal bone marrow (n = 10).
|
16645202 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
|
16001431 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
A new AHI-1-BCR-ABL-JAK2 interaction complex has recently been identified and this complex regulates transforming activities and drug resistance in CML stem/progenitor cells.
|
22248740 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
A translocation generating the constitutively activated fusion protein PCM1-JAK2 has also been recently found in atypical chronic myelogenous leukemia and acute leukemia.
|
16007127 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities of tyrosine kinase proteins are well recognised in myeloid malignancies, mutation in the cytoplasmic tyrosine kinase JAK2 (V617F) is key in the pathogenesis of myeloproliferative neoplasms, and translocations involving ABL key in the development of chronic myeloid leukaemia.
|
21722956 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the JAK2/STAT3 signalling pathway, which is abnormally active in CML, was inhibited by MBD2 deletion, and MBD2 deletion could up-regulate the expression of SHP1.
|
29565710 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.
|
22733019 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
And finally, Will the benefits conferred by current or future JAK2(V617F) inhibitors equal or even surpass the clinical success that has resulted from the use of tyrosine kinase inhibitors in CML?
|
19641523 |
2009 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, which fall into distinct categories based on a number of characteristics including the presence of the BCR-ABL1 gene fusion (chronic myelogenous leukemia) or the JAK2(V617F) mutation (polycythemia vera, primary myelofibrosis, and essential thrombocythemia).
|
22847163 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Consequently, JAK2 inhibitors represent promising molecular therapeutic tools in CML.
|
29423056 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Considerable effort is being made to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients.
|
27282563 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
LHGDN |
Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion.
|
15676212 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.
|
20809224 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.
|
31366526 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However it is not so easy, because iPSCs from hematological malignancies have been established only from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.
|
23807288 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, a proportion of wild-type JAK2 non-chronic myelogenous leukemia chronic myeloproliferative disorders cases also demonstrate this abnormal pSTAT5 expression pattern.
|
18479730 |
2008 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
In myeloid diseases we have seen dramatic improvements in the overall survival and quality of life for patients with chronic myeloid leukaemia treated with ABL and Src/ABL kinase inhibitors and we are poised to discover whether JAK2 inhibitors may offer similar benefit in myeloproliferative diseases.
|
20041451 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we used mice with a conditional null mutation in the Stat5a/b gene locus to determine the requirement for STAT5 in MPNs induced by BCR-ABL1 and JAK2(V617F) in retroviral transplantation models of CML and PV.
|
22234689 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of JAK-2 overcomes GM-CSF-induced IM and NI progenitor cell resistance, providing a rationale for the application of JAK-2 inhibitors to eradicate residual disease in CML.
|
17090651 |
2007 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
JAK2V617F, a somatic gain-of-function mutation involving the JAK2 tyrosine kinase gene, occurs in nearly all patients with polycythemia vera (PV) but also in a variable proportion of patients with other myeloid disorders; mutational frequency is estimated at approximately 50% in both essential thrombocythemia (ET) and myelofibrosis (MF), up to 20% in certain subcategories of atypical myeloproliferative disorder (atypical MPD), less than 3% in de novo myelodysplastic syndrome (MDS) or acute myeloid leukemia, and 0% in chronic myeloid leukemia (CML).
|
17124067 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs.
|
29951914 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
LCN-2 mRNA showed a near 50-fold increase in expression, accompanied by down-regulation of SLC22A17, coinciding with increase in BCR-ABL transcripts, loss of JAK2-V617F and change of clinical phenotype from polycythaemia vera to chronic myeloid leukaemia.
|
21950422 |
2012 |